PROJECT SUMMARY
Next generation sequencing (NGS) technologies have revolutionized the world of genomics, transcriptomics and
epigenomics. Core facilities play a critical role in academic institutions by providing access to the specialized
expertise and instrumentation that are frequently out of reach to individual research laboratories. The Genomic
and RNA Profiling (GARP) Core at Baylor College of Medicine (BCM) has over 12 years of experience in
operating and administering next-generation sequencers and provides sequencing services for well over 100
investigators per year. The requested instrument, the Illumina NovaSeq X, is the latest Illumina next-generation
sequencer that will replace our existing Illumina NovaSeq 6000 and enable the core to meet the rapidly changing
and growing needs of investigators at BCM. The major advances of the NovaSeq X, important for our needs
going forward, are greater output and flexibility, long-read sequencing applications, an integrated data analysis
platform, a smaller data footprint and reduced sequencing costs. To assure an optimal infrastructure and
maximum accessibility to BCM researchers, the Illumina NovaSeq X sequencer will be maintained and operated
by the GARP Core. We anticipate that the new instrument will support all of our established Illumina library prep
applications as well as allow for new applications and future growth. Most importantly, the NovaSeq X will enable
the GARP Core to remain the sequencing hub for the majority of investigators, postdocs and students at BCM
and extend support to surrounding Texas Medical Center institutions. The new instrument will enable us to
continue highly customized research projects that require control over every step of our NGS operation starting
with consultation and experimental design, sample processing, library construction, quality control and
management, and delivery of sequencing data and applying high quality standards throughout the entire process.
As the GARP Core develops additional epigenomics assays, the NovaSeq X will ensure capacity for new
applications and ensure that we can offer them as one-stop workflows to the local research community.
This new instrument will empower groups at BCM from a broad range of disciplines to understand the molecular
mechanisms of human diseases. We have identified 19 participating groups with NIH funding engaged in both
basic and clinical research that will benefit from the NovaSeq X sequencer. We believe the introduction of this
new NGS instrument will have direct, broad, and immediate impact on many medically relevant fields.